Chief Business Officer · Immunome Inc. (IMNM)

Kinney Horn

FY2024 is the first fiscal year CompBrief holds for Kinney Horn as a named executive officer of Immunome; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$6,989,668

Salary $382,765Stock awards $0Bonus $25,000

2nd of 3 named executive officers at Immunome by FY2024 total.

3 named officers on file for Immunome, FY2024

Kinney Horn’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunome’s whole pay program stands against its peers

  • Immunome’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMNM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Kinney Horn’s full pay file as a PDF — free

More than this page: up to 10 years of Kinney’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Kinney Horn compensation by year

Immunome Summary Compensation Table · the one fiscal year held
In US dollars, as Immunome reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$382,765
Bonus$25,000
Stock awards$0
Option awards$6,390,806
Non-equity incentive$180,747
Pension and deferred compensation$0
All other$10,350
Total$6,989,668

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunome Inc. DEF 14A filed April 24, 2025, accession 0001140361-25-015421, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunome Inc. filed document, accession 0001140361-25-015421. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option300,000—$23.00
Option130,000—$12.92

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunome Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

11 Form 4 lines since the FY2024 proxy (filed April 24, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-08-04Sale10b5-190,616$25.090
2026-08-04Exercise or conversion derivative10b5-150,366$0.0078,542
2026-08-04Exercise or conversion10b5-150,366$12.9250,366
2026-08-04Exercise or conversion derivative10b5-140,250$0.00120,750
2026-08-04Exercise or conversion10b5-140,250$10.6090,616
2026-07-23Grant or award—31,250$0.0031,250
2026-07-23Grant or award derivative—62,500$0.0062,500
2026-07-07Exercise or conversion10b5-11,092$12.921,092

The 8 most recent of 11 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Immunome’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Clay SiegallPresident, Chief Executive Officer and Chairman of the Board$9,226,774
Kinney Horn · this pageChief Business Officer$6,989,668
Sandra StonemanChief Legal Officer$5,246,699

The full Immunome compensation record

free company brief

This page is one person within Immunome's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunome's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kinney Horn's compensation dossier · One-time report. No refunds.